Osteopontin is down-regulated in hydatidiform mole

Gynecologic Oncology

Volumn 89, Issue 1, 2003, Pages 134-139

  Batorfi, Jozsef ^b   Fulop, Vilmos ^b   Kim, Jae Hoon ^c   Genest, David R ^a   Doszpod, Jozsef ^b   Mok, Samuel C ^a   Berkowitz, Ross S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b National Health Center   (Hungary)

^c The Catholic University of Korea   (South Korea)

Author keywords

Hydatidiform mole; Immunohistochemistry; Laser capture microdissection; LCM; OPN; Osteopontin; Placenta; Real time PCR

Indexed keywords

OSTEOPONTIN;

ARTICLE; CARCINOGENESIS; CHROMOSOME MICRODISSECTION; DOWN REGULATION; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PLACENTA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TROPHOBLAST;

EID: 0345701468     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00067-2     Document Type: Article

References (39)

1. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults regulation of inflammations, tissue remodeling, and cell survival . J Clin Invest. 107:2001;1055-1061.
2. Hu D.D., Lin E.C., Kovach N.L., Hoyer J.R., Smith J.W. A biochemical characterization of the binding of osteopontin to integrins aVb1 and aVb5. J Biol Chem. 270:1995;26232-26238.
3. Kim Y.W., Park Y.-K., Lee J., Ko S.W., Yang M.H. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci. 13:1998;652-657.
4. Xie Y., Sakatsume M., Nishi S., Narita I., Arakawa M., Gejyo F. Expression, roles, receptors and regulation of osteopontin in the kidney. Kidney Int. 60:2001;1645-1657.
5. Ihara H., Denhardt D.T., Furuya K., Yamashita T., Muguruma Y., Tsuji K., Hruska K.A., Higashio K., Enomoto S., Nifuji A., Rittling S.R., Noda M. Parathyroid hormone-induced bone resorption does not occure in the absence of osteopontin. J Biol Chem. 276:2001;13065-13071. (doi: 10.1047/jbc.M010938200).
6. Yoshitake H.Y., Rittling S.R., Denhardt D.T., Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA. 96:1999;8156-8160.
7. Nemir M., Bhattacharyya D., Li X., Singh K., Mukherjee A.B., Mukherjee B.B. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem. 275:2000;969-976.
8. Weintraub A.S., Schnapp L.M., Lin X., Taubman M.B. Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Lab Invest. 80:2000;1603-1615.
9. Omigbodun A., Ziolkiewicz P., Tessler C., Hoyer J.R., Coutifaris C. Progesterone regulates osteopontin expression in human trophoblasts a model of paracrine control in the placenta? Endocrinology. 138:1997;4308-4315.
10. Apparao K.B., Murray M.J., Fritz M.A., Meyer W.R., Chambers A.F., Truong P.R., Lessey B.A. Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab. 86:2001;4991-5000.
11. Johnson G.A., Spencer T.E., Burghardt R.C., Taylor K.M., Gray C.A., Bazer F.W. Progesterone modulation of osteopontin gene expression in the ovine uterus. Biol Reprod. 62:2000;1315-1321.
12. 3 integrin expression in the uterus and conceptus during the periinplantation period. Biol Reprod. 61:1999;892-899.
13. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., Berkowitz R.S., Cramer D.W., Mok S.C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc. 287:2002;1671-1679.
14. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W.K. Osteopontin possible role in prostate cancer progression . Clin Cancer Res. 5:1999;2271-2277.
15. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., Casson A.G. Osteopontin expression in lung cancer. Lung Cancer. 15:1996;311-323.
16. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 94:2002;513-521.
17. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 79:1998;127-132.
18. Gotoh M., Sakamoto M., Kanetaka K., Chuuma M., Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 52:2002;19-24.
19. Takahashi F., Akatugawa S., Fukumoto H., Tsukiyama S., Ohe Y., Takahashi K., Fukuchi Y., Saijo N., Nishio K. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer. 98:2002;707-712.
20. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-Kb-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 276:2001;44926-44935. . (doi: 10.1074/jbc.M103334200).
21. Kohorn E.I. Hydatidiform mole and gestational trophoblastic disease in Southern Connecticut. Obstet Gynecol. 59:1982;78-84.
22. Lurain J.R., Brewer J.I., Torok E.E., Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol. 145:1983;591-595.
23. Soper J.T., Clarke-Pearson D., Hammond C.B. Metastatic gestational trophoblastic disease prognostic factors in previously untreated patients . Obstet Gynecol. 71:1988;338-343.
24. Berkowitz R.S., Goldstein D.P. Chorionic tumors. N Engl J Med. 335:1996;1740-1748.
25. Seckl M.J., Fisher R.A., Salerno G., Rees H., Paradinas F.J., Foskett M., Newlands E.S. Choriocarcinoma and partial hydatidiform moles. Lancet. 356:2000;36-39.
26. Sirivatanauksorn Y., Drury R., Crnogorac-Jurcevic T., Sirivatanauksorn V., Lemoine N.R. Laser-assisted microdissection applications in molecular pathology . J Pathol. 189:1999;150-154.
27. Simone N.L., Paweletz C.P., Charboneau L., Petricoin E.F., Liotta L.A. Laser capture microdissection beyond functional genomics to proteomics . Mol Diagn. 5:2000;301-307. (doi: 10.1054/modi.2000.19808).
28. Rodriguez G.C., Hughes C.L., Soper J.T., Berchuck A., Clarke-Pearson D.L., Hammond C.B. Serum progesterone for exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia. Obstet Gynecol. 84:1994;794-797.
29. Genti-Raimondi S., Alvarez C.I., Patrito L.C., Flury A. Low aromatase activity in microsomes from complete hydatidiform mole. J Clin Endocrinol Metab. 76:1993;108-111.
30. Ho P.C., Wong L.C., Ma H.K. Plasma prolactin, progesterone, estradiol, and human chorionic gonadotropin in complete and partial moles before and after evacuation. Obstet Gynecol. 67:1986;99-106.
31. Cseh I., Szepesi J., Walentin S., Szabo T., Dravucz S., Szalay J., Gati I. Significance of the determination of estrogen and progesterone receptors in trophoblast diseases. Zentralbl Gynacol. 112:1990;151-159.
32. Cheung A.N., Ngan H.Y., Ng W.F., Khoo U.S. The expression of cathepsin D, oestrogen receptor and progestogen receptor in hydatidiform mole - an immunohistochemical study. Histopathology. 27:1995;341-347.
33. Fulop V., Mok S.C., Gati I., Berkowitz R.S. Recent advances in molecular biology of gestational trophoblastic diseases. J Reprod Med. 47:2002;369-379.
34. Bischof P., Martelli M., Campana A. The regulation of endometrial and trophoblastic metalloproteinases during blastocyst implantation and placentation. Contracept Fertil Sex. 22:1994;48-52.
35. Fulop V., Mok S.C., Genest D.R., Gati I., Doszpod J., Berkowitz R.S. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med. 43:1998;119-127.
36. Tuncer Z.S., Vegh G.L., Fulop V., Genest D.R., Mok S.C., Berkowitz R.S. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol. 77:2000;389-393. (doi: 10.1006/gyno.2000.5777).
37. Ohlsson R. Growth factors, protooncogenes and human placental development. Cell Growth Differ. 28:1989;1-15.
38. Vegh G.L., Selcuk Tuncer Z., Fulop V., Genest D.R., Mok S.C., Berkowitz R.S. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol. 75:1999;248-253. (doi: 10.1006/gyno.1999.5564).
39. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:1996;683-693.